EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio

– Patent Covers 38 European Countries –

– Rencofilstat’s Exclusivity May Extend into 2048 –

EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that the European Patent Office (“EPO”) has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat.

Read more at globenewswire.com